Importer of Controlled Substances; Notice of Application, 20000-20001 [2010-8792]
Download as PDF
20000
Federal Register / Vol. 75, No. 73 / Friday, April 16, 2010 / Notices
SUMMARY: This order extends the
withdrawal created by Public Land
Order No. 6776 for an additional 20-year
period. This extension is necessary to
continue protection of the North
Cascades Scenic Highway Zone in
Chelan, Okanogan, Skagit, and
Whatcom Counties, Washington which
would otherwise expire on April 17,
2010.
DATES: Effective Date: April 18, 2010.
FOR FURTHER INFORMATION CONTACT:
Gregory B. Graham, U.S. Forest Service
Okanogan-Wenatchee National Forest,
215 Melody Lane, Wenatchee,
Washington 98801, (509) 664–9262, or
Charles R. Roy, Bureau of Land
Management Oregon/Washington State
Office, P.O. Box 2965, Portland, Oregon
97208, (503) 808–6189.
SUPPLEMENTARY INFORMATION: The
purpose for which the withdrawal was
first made requires this extension to
continue protection of the unique
natural, scenic, and recreational values
and the investment of Federal funds
along the North Cascades Scenic
Highway Zone within the Mt. Baker,
Okanogan, and Wenatchee National
Forest. The United States Forest Service
will continue to manage the lands to
protect these values.
Order
By virtue of the authority vested in
the Secretary of the Interior by Section
204 of the Federal Land Policy and
Management Act of 1976, 43 U.S.C.
1714, it is ordered as follows:
1. Public Land Order No. 6776 (55 FR
14422, (1990)) that withdrew 8,950
acres of National Forest System lands
from location or entry under the United
States mining laws (30 U.S.C. ch. 2) on
behalf of the Forest Service to protect
the North Cascades Scenic Highway
Zone, is hereby extended for an
additional 20-year period.
2. Public Land Order No. 6776 will
expire on April 17, 2030, unless, as a
result of a review conducted prior to the
expiration date, pursuant to Section
204(f) of the Federal Land Policy
Management Act of 1976, 43 U.S.C.
1714(f), the Secretary of the Interior
determines that the withdrawal shall be
extended.
Dated: April 9, 2010.
Wilma A. Lewis,
Assistant Secretary—Land and Minerals
Management.
[FR Doc. 2010–8778 Filed 4–15–10; 8:45 am]
BILLING CODE 3410–11–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–10–011]
Government in the Sunshine Act
Meeting Notice; Change of Time of
Commission Meeting
United
States International Trade Commission.
ORIGINAL DATE AND TIME: April 15, 2010
at 11 a.m.
NEW DATE AND TIME: April 15, 2010 at
2:30 p.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
In accordance with 19 CFR 201.37(a),
the Commission has determined to
AGENCY HOLDING THE MEETING:
reschedule the above referenced
Commission meeting from 11 a.m. to
2:30 p.m. on April 15, 2010. Earlier
announcement of this rescheduling was
not possible.
Issued: April 13, 2010.
By order of the Commission.
William R. Bishop,
Hearings and Meetings Coordinator.
[FR Doc. 2010–8852 Filed 4–14–10; 11:15 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on
February 15, 2010, Lipomed, Inc., One
Broadway, Cambridge, Massachusetts
02142, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedules I and II:
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Drug
Schedule
Cathinone (1235) .........................................................................................................................................................................................
Methcathinone (1237) ..................................................................................................................................................................................
N-Ethylamphetamine (1475) ........................................................................................................................................................................
Fenethylline (1503) ......................................................................................................................................................................................
Methaqualone (2565) ..................................................................................................................................................................................
Gamma Hydroxybutyric Acid (2010) ...........................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) ...............................................................................................................................
Marihuana (7360) ........................................................................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
Mescaline (7381) .........................................................................................................................................................................................
3,4,5-Trimethoxyamphetamine (7390) ........................................................................................................................................................
4–Bromo-2,5-dimethoxyamphetamine (7391) .............................................................................................................................................
4–Bromo-2,5-dimethoxyphenethylamine (7392) .........................................................................................................................................
4–Methyl-2,5-dimethoxyamphetamine (7395) .............................................................................................................................................
2,5–Dimethoxyamphetamine (7396) ...........................................................................................................................................................
2,5–Dimethoxy-4-ethylamphetamine (7399) ...............................................................................................................................................
3,4–Methylenedioxyamphetamine (7400) ...................................................................................................................................................
3,4–Methylenedioxy-N-ethylamphetamine (7404) .......................................................................................................................................
3,4–Methylenedioxymethamphetamine (7405) ...........................................................................................................................................
4–Methoxyamphetamine (7411) ..................................................................................................................................................................
Dimethyltryptamine (7435) ..........................................................................................................................................................................
Psilocybin (7437) .........................................................................................................................................................................................
Psilocyn (7438) ............................................................................................................................................................................................
N–Benzylpiperazine (7493) .........................................................................................................................................................................
VerDate Nov<24>2008
15:07 Apr 15, 2010
Jkt 220001
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
E:\FR\FM\16APN1.SGM
16APN1
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
20001
Federal Register / Vol. 75, No. 73 / Friday, April 16, 2010 / Notices
Drug
Schedule
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Acetyldihydrocodeine (9051) .......................................................................................................................................................................
Dihydromorphine (9145) ..............................................................................................................................................................................
Heroin (9200) ...............................................................................................................................................................................................
Normorphine (9313) ....................................................................................................................................................................................
Pholcodine (9314) .......................................................................................................................................................................................
Tilidine (9750) ..............................................................................................................................................................................................
3–Methylfentanyl (9813) ..............................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Methylphenidate (1724) ...............................................................................................................................................................................
Amobarbital (2125) ......................................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Secobarbital (2315) .....................................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Cocaine (9041) ............................................................................................................................................................................................
Codeine (9050) ............................................................................................................................................................................................
Dihydrocodeine (9120) ................................................................................................................................................................................
Oxycodone (9143) .......................................................................................................................................................................................
Hydromorphone (9150) ...............................................................................................................................................................................
Benzoylecgonine (9180) ..............................................................................................................................................................................
Ethylmorphine (9190) ..................................................................................................................................................................................
Hydrocodone (9193) ....................................................................................................................................................................................
Levorphanol (9220) .....................................................................................................................................................................................
Meperidine (9230) .......................................................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) (9273) ..............................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Alfentanil (9737) ..........................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration, and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 17, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
VerDate Nov<24>2008
15:07 Apr 15, 2010
Jkt 220001
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–8792 Filed 4–15–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 23, 2010,
Siemens Healthcare Diagnostics Inc.,
Attn: RA, 100 GBC Drive, Mail Stop 514,
Newark, Delaware 19702, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Drug
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Schedule
I
II
II
The company utilizes the listed
controlled substances in bulk to
manufacture in-vitro diagnostic test kits.
The company distributes the test kits for
sale to its customers. The process used
in manufacturing the test kits
irreversibly alters the controlled
substances involved in such a manner
that they are no longer classified as
controlled substances as defined under
the Controlled Substances Act.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 15, 2010.
E:\FR\FM\16APN1.SGM
16APN1
Agencies
[Federal Register Volume 75, Number 73 (Friday, April 16, 2010)]
[Notices]
[Pages 20000-20001]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-8792]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on February 15, 2010, Lipomed,
Inc., One Broadway, Cambridge, Massachusetts 02142, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of the basic classes of controlled substances listed in
schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)............................ I
Methcathinone (1237)........................ I
N-Ethylamphetamine (1475)................... I
Fenethylline (1503)......................... I
Methaqualone (2565)......................... I
Gamma Hydroxybutyric Acid (2010)............ I
Lysergic acid diethylamide (7315)........... I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine I
(7348).
Marihuana (7360)............................ I
Tetrahydrocannabinols (7370)................ I
Mescaline (7381)............................ I
3,4,5-Trimethoxyamphetamine (7390).......... I
4-Bromo-2,5-dimethoxyamphetamine (7391)..... I
4-Bromo-2,5-dimethoxyphenethylamine (7392).. I
4-Methyl-2,5-dimethoxyamphetamine (7395).... I
2,5-Dimethoxyamphetamine (7396)............. I
2,5-Dimethoxy-4-ethylamphetamine (7399)..... I
3,4-Methylenedioxyamphetamine (7400)........ I
3,4-Methylenedioxy-N-ethylamphetamine (7404) I
3,4-Methylenedioxymethamphetamine (7405).... I
4-Methoxyamphetamine (7411)................. I
Dimethyltryptamine (7435)................... I
Psilocybin (7437)........................... I
Psilocyn (7438)............................. I
N-Benzylpiperazine (7493)................... I
[[Page 20001]]
Acetyldihydrocodeine (9051)................. I
Dihydromorphine (9145)...................... I
Heroin (9200)............................... I
Normorphine (9313).......................... I
Pholcodine (9314)........................... I
Tilidine (9750)............................. I
3-Methylfentanyl (9813)..................... I
Amphetamine (1100).......................... II
Methamphetamine (1105)...................... II
Methylphenidate (1724)...................... II
Amobarbital (2125).......................... II
Pentobarbital (2270)........................ II
Secobarbital (2315)......................... II
Phencyclidine (7471)........................ II
Phenylacetone (8501)........................ II
Cocaine (9041).............................. II
Codeine (9050).............................. II
Dihydrocodeine (9120)....................... II
Oxycodone (9143)............................ II
Hydromorphone (9150)........................ II
Benzoylecgonine (9180)...................... II
Ethylmorphine (9190)........................ II
Hydrocodone (9193).......................... II
Levorphanol (9220).......................... II
Meperidine (9230)........................... II
Methadone (9250)............................ II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................. II
Thebaine (9333)............................. II
Oxymorphone (9652).......................... II
Alfentanil (9737)........................... II
Sufentanil (9740)........................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to import analytical reference standards for
distribution to its customers for research and analytical purposes.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances may file comments or objections to the issuance of the
proposed registration, and may, at the same time, file a written
request for a hearing on such application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than May 17, 2010.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substance in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: March 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-8792 Filed 4-15-10; 8:45 am]
BILLING CODE 4410-09-P